Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Thomas H. Langenickel

Single Therapeutic and Supratherapeutic Doses of Sacubitril/Valsartan (LCZ696) Do Not Affect Cardiac Repolarization

European Journal of Clinical Pharmacology
MedicinePharmacology
2016English

KIS Protects Against Adverse Vascular Remodeling by Opposing Stathmin-Mediated VSMC Migration in Mice

Journal of Clinical Investigation
Medicine
2008English

Related publications

Single Therapeutic and Supra‐Therapeutic Doses of Ubrogepant Do Not Affect Cardiac Repolarization in Healthy Adults: Results From a Randomized Trial

Clinical Pharmacology and Therapeutics
Pharmacology
2019English

LCZ696 (Sacubitril/Valsartan), an Angiotensin-Receptor Neprilysin Inhibitor, Attenuates Cardiac Hypertrophy, Fibrosis and Vasculopathy in a Rat Model of Chronic Kidney Disease

Journal of Cardiac Failure
Cardiovascular MedicineCardiology
2018English

Potential Markers of Sacubitril-Valsartan Tolerance

Journal of Cardiac Failure
Cardiovascular MedicineCardiology
2019English

Sacubitril/Valsartan Use for the Hospitalist

American Journal of Hospital Medicine
2017English

Sacubitril/Valsartan: Beyond Natriuretic Peptides

Heart
Cardiovascular MedicineCardiology
2017English

Sacubitril-Valsartan in Heart Failure and Multimorbidity Patients

ESC heart failure
Cardiovascular MedicineCardiology
2018English

Sacubitril/Valsartan Verbessern Auch Den HbA1c-Wert

MMW Fortschritte der Medizin
Medicine
2017English

Bedtime Doses of Prazosin Do Not Affect Daytime Salivary Amylase Markers in PTSD

Heliyon
Multidisciplinary
2019English

Sacubitril/Valsartan: Evaluation of Safety and Efficacy as an Antihypertensive Treatment

Drugs in Context
Molecular MedicinePharmacology
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy